Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

6.52
+0.30004.82%
Post-market: 6.520.00000.00%19:29 EST
Volume:2.01M
Turnover:13.15M
Market Cap:1.16B
PE:-14.45
High:6.69
Open:6.35
Low:6.29
Close:6.22
52wk High:6.88
52wk Low:1.33
Shares:177.86M
Float Shares:123.05M
Volume Ratio:0.81
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4512
EPS(LYR):-0.3594
ROE:-37.82%
ROA:-23.47%
PB:5.53
PE(LYR):-18.14

Loading ...

Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and Compass Therapeutics (CMPX)

TIPRANKS
·
Jan 28

Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum

Simply Wall St.
·
Jan 17

Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale?

Simply Wall St.
·
Jan 16

Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential

TIPRANKS
·
Jan 11

Compass Therapeutics (CMPX) Gets a Buy from Canaccord Genuity

TIPRANKS
·
Jan 08

Compass Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 06

Compass Therapeutics Reports Pipeline Progress and $209 Million Cash Runway Into 2028

Reuters
·
Jan 06

Compass Therapeutics: Initiation of Phase 2 Trial of Ctx-471 in Patients With Tumors Expressing Ncam (Cd56) Expected H1 2026

THOMSON REUTERS
·
Jan 06

Compass Therapeutics Inc. - Pfs and Os Analyses for Tovecimig in BTC on Track for Q1 2026

THOMSON REUTERS
·
Jan 06

Compass Therapeutics Inc. - Phase 1 Study of Ctx-10726 Expected to Start in Q1 2026, Initial Data Expected H2 2026

THOMSON REUTERS
·
Jan 06

Compass Therapeutics Provides Corporate Update

GlobeNewswire
·
Jan 06

Compass Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Cynthia Sirard

Reuters
·
Jan 06

BRIEF-Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jan 06

Compass Therapeutics Grants Stock Options to New Employees Under 2025 Inducement Plan

Reuters
·
Jan 06

Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care

Benzinga
·
Jan 06

Compass Therapeutics Initiated at Outperform by William Blair

Dow Jones
·
Jan 05

Compass Therapeutics Appoints Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer

Reuters
·
Jan 05

Press Release: Compass Therapeutics Announces Key Leadership Appointments

Dow Jones
·
Jan 05

William Blair Initiates Compass Therapeutics at Outperform

MT Newswires Live
·
Jan 05

BRIEF-Compass Therapeutics Files For Up To $400 Million Mixed Shelf Offering- SEC Filing

Reuters
·
Dec 31, 2025